Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10501 in healthy subjects
NCT06359600Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Mar 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HS-10501 in type 2 diabetes mellitus (T2DM) and obesity (9 cohorts), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Incidence and severity of adverse events(AE) , serious AEs and AE leading to withdrawal from treatment, Number of participants with clinically significant abnormalities in lab tests and 2 more. Started Mar 2024; status: recruiting.
02
Drugs
HS-10501
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06359600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06359600.